Jennifer Richer
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 16 | 2025 | 220 | 6.210 |
Why?
| | Receptors, Androgen | 14 | 2025 | 154 | 5.650 |
Why?
| | Breast Neoplasms | 48 | 2026 | 2520 | 4.640 |
Why?
| | MicroRNAs | 17 | 2018 | 703 | 3.540 |
Why?
| | Androgen Receptor Antagonists | 8 | 2021 | 35 | 2.290 |
Why?
| | Cell Line, Tumor | 41 | 2026 | 3634 | 2.120 |
Why?
| | Anoikis | 7 | 2021 | 30 | 2.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 35 | 2025 | 1498 | 2.020 |
Why?
| | Receptors, Estrogen | 15 | 2025 | 470 | 2.000 |
Why?
| | Phenylthiohydantoin | 7 | 2025 | 44 | 1.860 |
Why?
| | Tryptophan | 4 | 2024 | 180 | 1.840 |
Why?
| | Receptors, Progesterone | 24 | 2016 | 353 | 1.740 |
Why?
| | Estrogen Receptor alpha | 6 | 2022 | 161 | 1.710 |
Why?
| | Tryptophan Oxygenase | 5 | 2024 | 33 | 1.580 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 597 | 1.080 |
Why?
| | Palmitates | 1 | 2025 | 21 | 0.940 |
Why?
| | Progesterone | 16 | 2014 | 256 | 0.940 |
Why?
| | Neoplasm Invasiveness | 4 | 2024 | 519 | 0.940 |
Why?
| | Benzamides | 8 | 2026 | 226 | 0.930 |
Why?
| | Heme | 1 | 2026 | 89 | 0.920 |
Why?
| | Progestins | 6 | 2014 | 87 | 0.890 |
Why?
| | Tamoxifen | 10 | 2016 | 218 | 0.890 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 901 | 0.870 |
Why?
| | Oxidative Phosphorylation | 1 | 2025 | 211 | 0.850 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 57 | 0.850 |
Why?
| | Ribonuclease III | 2 | 2016 | 44 | 0.800 |
Why?
| | Neoplastic Stem Cells | 3 | 2017 | 413 | 0.780 |
Why?
| | DEAD-box RNA Helicases | 2 | 2016 | 90 | 0.770 |
Why?
| | Wound Healing | 1 | 2026 | 361 | 0.770 |
Why?
| | Epithelial Cells | 3 | 2022 | 1134 | 0.770 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2018 | 225 | 0.750 |
Why?
| | Adipokines | 2 | 2024 | 58 | 0.740 |
Why?
| | Biomarkers, Tumor | 7 | 2021 | 1334 | 0.730 |
Why?
| | Tumor Microenvironment | 7 | 2026 | 743 | 0.730 |
Why?
| | Cell Proliferation | 14 | 2021 | 2545 | 0.720 |
Why?
| | Kallikreins | 1 | 2021 | 24 | 0.710 |
Why?
| | Nitriles | 7 | 2025 | 205 | 0.700 |
Why?
| | Gene Expression Profiling | 11 | 2018 | 1829 | 0.670 |
Why?
| | Female | 67 | 2026 | 78355 | 0.670 |
Why?
| | Prostate-Specific Antigen | 1 | 2021 | 158 | 0.670 |
Why?
| | Membrane Transport Proteins | 1 | 2021 | 154 | 0.640 |
Why?
| | Mice | 26 | 2026 | 18562 | 0.640 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 177 | 0.640 |
Why?
| | Immunohistochemistry | 8 | 2017 | 1735 | 0.640 |
Why?
| | Endometrial Neoplasms | 6 | 2011 | 208 | 0.630 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2023 | 1148 | 0.630 |
Why?
| | Transcription Factors | 13 | 2023 | 1742 | 0.620 |
Why?
| | Trophoblasts | 1 | 2022 | 219 | 0.620 |
Why?
| | Humans | 95 | 2026 | 145077 | 0.620 |
Why?
| | Pulmonary Alveoli | 1 | 2022 | 393 | 0.620 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2021 | 180 | 0.610 |
Why?
| | Cell Movement | 9 | 2020 | 978 | 0.610 |
Why?
| | Androgen Antagonists | 3 | 2017 | 92 | 0.610 |
Why?
| | Animals | 41 | 2026 | 38352 | 0.600 |
Why?
| | Mammary Glands, Animal | 4 | 2022 | 131 | 0.600 |
Why?
| | Homeodomain Proteins | 5 | 2014 | 525 | 0.590 |
Why?
| | Repressor Proteins | 6 | 2018 | 435 | 0.580 |
Why?
| | Alternative Splicing | 2 | 2018 | 248 | 0.580 |
Why?
| | Macrophages | 2 | 2026 | 1533 | 0.570 |
Why?
| | Lung Neoplasms | 2 | 2026 | 2645 | 0.570 |
Why?
| | Cell Cycle | 4 | 2021 | 632 | 0.560 |
Why?
| | Up-Regulation | 7 | 2020 | 864 | 0.560 |
Why?
| | RNA Splicing Factors | 1 | 2018 | 64 | 0.550 |
Why?
| | Mammary Neoplasms, Experimental | 3 | 2017 | 71 | 0.550 |
Why?
| | Carcinoma, Endometrioid | 2 | 2008 | 51 | 0.500 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2021 | 951 | 0.500 |
Why?
| | Gonadal Steroid Hormones | 1 | 2018 | 145 | 0.490 |
Why?
| | Lactation | 2 | 2022 | 194 | 0.490 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.480 |
Why?
| | Antibody Specificity | 1 | 2016 | 185 | 0.470 |
Why?
| | MCF-7 Cells | 4 | 2025 | 138 | 0.470 |
Why?
| | Paclitaxel | 3 | 2017 | 256 | 0.470 |
Why?
| | Receptor, trkB | 2 | 2012 | 36 | 0.460 |
Why?
| | Signal Transduction | 19 | 2025 | 5282 | 0.460 |
Why?
| | Antineoplastic Agents | 6 | 2018 | 2225 | 0.450 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2015 | 61 | 0.440 |
Why?
| | Apoptosis | 11 | 2020 | 2455 | 0.440 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.430 |
Why?
| | Kynurenine | 4 | 2024 | 113 | 0.420 |
Why?
| | RNA Interference | 3 | 2015 | 482 | 0.420 |
Why?
| | Antibodies | 1 | 2016 | 402 | 0.410 |
Why?
| | Receptors, Steroid | 2 | 2010 | 46 | 0.400 |
Why?
| | Metformin | 2 | 2014 | 332 | 0.400 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 453 | 0.400 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2025 | 49 | 0.380 |
Why?
| | Gene Expression Regulation | 8 | 2016 | 2633 | 0.380 |
Why?
| | Chromatin | 1 | 2016 | 557 | 0.360 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 949 | 0.360 |
Why?
| | Mutation | 8 | 2025 | 4132 | 0.360 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2012 | 78 | 0.350 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 56 | 0.350 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2024 | 84 | 0.350 |
Why?
| | Neoplasm Metastasis | 4 | 2026 | 706 | 0.340 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 467 | 0.340 |
Why?
| | Antineoplastic Agents, Hormonal | 5 | 2020 | 196 | 0.340 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1968 | 0.340 |
Why?
| | Disease Progression | 6 | 2018 | 2884 | 0.340 |
Why?
| | Endometrium | 2 | 2008 | 62 | 0.330 |
Why?
| | NF-kappa B | 3 | 2025 | 671 | 0.330 |
Why?
| | Transcriptional Activation | 5 | 2017 | 382 | 0.320 |
Why?
| | Mice, SCID | 4 | 2020 | 377 | 0.320 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 342 | 0.300 |
Why?
| | Tubulin Modulators | 1 | 2009 | 11 | 0.300 |
Why?
| | Cells | 1 | 2009 | 25 | 0.300 |
Why?
| | 3' Untranslated Regions | 4 | 2014 | 153 | 0.290 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 4 | 2011 | 23 | 0.290 |
Why?
| | Estradiol | 6 | 2016 | 540 | 0.290 |
Why?
| | Uterine Neoplasms | 2 | 2008 | 96 | 0.290 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 475 | 0.290 |
Why?
| | Cadherins | 4 | 2012 | 201 | 0.290 |
Why?
| | Dirofilaria immitis | 3 | 2010 | 3 | 0.270 |
Why?
| | Mice, Nude | 5 | 2017 | 692 | 0.270 |
Why?
| | Neoplasms | 5 | 2022 | 2932 | 0.260 |
Why?
| | Feedback, Physiological | 2 | 2021 | 84 | 0.260 |
Why?
| | Trastuzumab | 2 | 2017 | 120 | 0.250 |
Why?
| | Cell Nucleus | 5 | 2017 | 620 | 0.250 |
Why?
| | Transfection | 5 | 2012 | 953 | 0.250 |
Why?
| | Microtubules | 1 | 2009 | 287 | 0.240 |
Why?
| | Epidermal Growth Factor | 4 | 2005 | 172 | 0.240 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2026 | 15 | 0.240 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2026 | 12 | 0.240 |
Why?
| | Genetic Diseases, Inborn | 2 | 2017 | 44 | 0.240 |
Why?
| | Cyclopropanes | 1 | 2026 | 83 | 0.240 |
Why?
| | Bilirubin | 1 | 2026 | 91 | 0.230 |
Why?
| | Heme Oxygenase-1 | 1 | 2026 | 77 | 0.230 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2026 | 145 | 0.220 |
Why?
| | Aminopyridines | 1 | 2026 | 130 | 0.220 |
Why?
| | Fibrillin-1 | 1 | 2024 | 6 | 0.220 |
Why?
| | Alveolar Epithelial Cells | 1 | 2026 | 120 | 0.220 |
Why?
| | Anilides | 2 | 2016 | 83 | 0.220 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 115 | 0.220 |
Why?
| | Mice, Inbred NOD | 3 | 2020 | 619 | 0.220 |
Why?
| | Marfan Syndrome | 1 | 2024 | 46 | 0.220 |
Why?
| | Down-Regulation | 6 | 2016 | 641 | 0.210 |
Why?
| | Gene Expression | 4 | 2020 | 1518 | 0.210 |
Why?
| | Microarray Analysis | 2 | 2016 | 119 | 0.210 |
Why?
| | Cell Differentiation | 1 | 2012 | 2064 | 0.210 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.200 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 766 | 0.200 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 441 | 0.200 |
Why?
| | Tumor Cells, Cultured | 11 | 2020 | 944 | 0.180 |
Why?
| | Milk Proteins | 2 | 1999 | 35 | 0.180 |
Why?
| | Mammary Glands, Human | 2 | 2014 | 68 | 0.180 |
Why?
| | Genetic Variation | 2 | 2024 | 992 | 0.180 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 98 | 0.180 |
Why?
| | Epithelium | 1 | 2022 | 316 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2018 | 688 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2022 | 82 | 0.170 |
Why?
| | Mice, Transgenic | 2 | 2017 | 2199 | 0.170 |
Why?
| | Estrogens | 3 | 2020 | 382 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 102 | 0.170 |
Why?
| | Promoter Regions, Genetic | 6 | 2014 | 1259 | 0.170 |
Why?
| | DNA-Binding Proteins | 6 | 2018 | 1495 | 0.160 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 450 | 0.160 |
Why?
| | Semaphorins | 1 | 2020 | 39 | 0.160 |
Why?
| | Epoxy Compounds | 1 | 2020 | 32 | 0.160 |
Why?
| | Androgens | 1 | 2021 | 188 | 0.160 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 337 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 68 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2022 | 384 | 0.150 |
Why?
| | Respiratory Mucosa | 1 | 2022 | 326 | 0.150 |
Why?
| | STAT5 Transcription Factor | 3 | 2014 | 53 | 0.150 |
Why?
| | Transcription, Genetic | 9 | 2012 | 1507 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 418 | 0.150 |
Why?
| | RNA, Messenger | 7 | 2011 | 2862 | 0.150 |
Why?
| | Mitochondria | 1 | 2025 | 989 | 0.140 |
Why?
| | Pregnancy | 3 | 2022 | 7200 | 0.140 |
Why?
| | Prolactin | 1 | 1998 | 92 | 0.140 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 646 | 0.140 |
Why?
| | Gene Amplification | 1 | 2018 | 121 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 717 | 0.140 |
Why?
| | Immunoblotting | 3 | 2010 | 307 | 0.130 |
Why?
| | Endometrial Hyperplasia | 2 | 2008 | 7 | 0.130 |
Why?
| | Binding Sites | 5 | 2016 | 1314 | 0.130 |
Why?
| | Antigens, CD | 1 | 2020 | 564 | 0.130 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2017 | 45 | 0.130 |
Why?
| | Cluster Analysis | 4 | 2008 | 531 | 0.130 |
Why?
| | Dihydrotestosterone | 1 | 2017 | 43 | 0.130 |
Why?
| | Histone Acetyltransferases | 3 | 2006 | 61 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 273 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 451 | 0.130 |
Why?
| | Estrogen Receptor Modulators | 3 | 2008 | 17 | 0.120 |
Why?
| | Neoplasm Transplantation | 2 | 2014 | 256 | 0.120 |
Why?
| | Heterografts | 1 | 2017 | 145 | 0.120 |
Why?
| | Everolimus | 1 | 2017 | 112 | 0.120 |
Why?
| | Cyclohexanes | 1 | 2016 | 23 | 0.120 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 219 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 2 | 2014 | 325 | 0.120 |
Why?
| | Enzyme Inhibitors | 3 | 2024 | 832 | 0.120 |
Why?
| | Trans-Activators | 4 | 2006 | 399 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 231 | 0.120 |
Why?
| | Hyaluronan Receptors | 2 | 2014 | 104 | 0.120 |
Why?
| | Placenta | 1 | 2022 | 780 | 0.110 |
Why?
| | Ovary | 1 | 2017 | 227 | 0.110 |
Why?
| | Transplantation, Heterologous | 2 | 2014 | 196 | 0.110 |
Why?
| | Genes | 1 | 2015 | 226 | 0.110 |
Why?
| | Genetic Association Studies | 1 | 2017 | 376 | 0.110 |
Why?
| | Phosphoproteins | 2 | 2008 | 348 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 136 | 0.110 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 829 | 0.110 |
Why?
| | Exome | 1 | 2015 | 239 | 0.100 |
Why?
| | Tosyl Compounds | 1 | 2014 | 16 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 378 | 0.100 |
Why?
| | Genes, Reporter | 2 | 2012 | 277 | 0.100 |
Why?
| | Ligands | 6 | 2023 | 674 | 0.100 |
Why?
| | Protein Transport | 1 | 2015 | 445 | 0.100 |
Why?
| | Sarcoma, Ewing | 1 | 2015 | 102 | 0.100 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 166 | 0.100 |
Why?
| | HEK293 Cells | 1 | 2016 | 752 | 0.100 |
Why?
| | In Situ Hybridization | 2 | 2010 | 320 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2024 | 2414 | 0.100 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1993 | 50 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2016 | 4178 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 103 | 0.100 |
Why?
| | Neurotrophin 3 | 1 | 2012 | 10 | 0.100 |
Why?
| | Cell Adhesion | 2 | 2012 | 457 | 0.100 |
Why?
| | Autocrine Communication | 1 | 2012 | 40 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2021 | 4605 | 0.090 |
Why?
| | Ketones | 1 | 1993 | 53 | 0.090 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2015 | 384 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1056 | 0.090 |
Why?
| | Metalloendopeptidases | 1 | 1992 | 62 | 0.090 |
Why?
| | Cysteine Endopeptidases | 1 | 1992 | 74 | 0.090 |
Why?
| | Aromatase Inhibitors | 2 | 2014 | 76 | 0.090 |
Why?
| | Family | 1 | 2017 | 694 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2012 | 138 | 0.090 |
Why?
| | Middle Aged | 7 | 2024 | 36003 | 0.090 |
Why?
| | Disease-Free Survival | 1 | 2014 | 772 | 0.090 |
Why?
| | Nuclear Proteins | 5 | 2000 | 755 | 0.090 |
Why?
| | Gene Silencing | 2 | 2014 | 204 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 153 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2023 | 750 | 0.090 |
Why?
| | Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 6 | 0.090 |
Why?
| | Receptors, Leptin | 1 | 2011 | 25 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 147 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 321 | 0.090 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 51 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2016 | 6068 | 0.080 |
Why?
| | GTPase-Activating Proteins | 1 | 2011 | 89 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 2105 | 0.080 |
Why?
| | Fibronectins | 1 | 2011 | 136 | 0.080 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Protein Biosynthesis | 2 | 2012 | 459 | 0.080 |
Why?
| | Cell Transdifferentiation | 1 | 2010 | 31 | 0.080 |
Why?
| | HeLa Cells | 5 | 2006 | 654 | 0.080 |
Why?
| | Retinoid X Receptors | 1 | 2010 | 38 | 0.080 |
Why?
| | Cyclins | 3 | 1999 | 94 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2010 | 346 | 0.080 |
Why?
| | DNA, Complementary | 4 | 2008 | 278 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2010 | 993 | 0.080 |
Why?
| | Breast | 2 | 2022 | 162 | 0.080 |
Why?
| | Protein Isoforms | 4 | 2006 | 405 | 0.080 |
Why?
| | Lung | 1 | 2022 | 4192 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2009 | 141 | 0.070 |
Why?
| | Prognosis | 3 | 2024 | 4260 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2911 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2023 | 210 | 0.070 |
Why?
| | Perilipin-1 | 1 | 2008 | 17 | 0.070 |
Why?
| | S100 Proteins | 1 | 2008 | 36 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1048 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3414 | 0.070 |
Why?
| | Leiomyoma | 1 | 2008 | 59 | 0.070 |
Why?
| | Drug Interactions | 1 | 2009 | 399 | 0.070 |
Why?
| | Aged | 5 | 2024 | 25862 | 0.070 |
Why?
| | Glycoproteins | 2 | 2024 | 357 | 0.060 |
Why?
| | Hysterectomy | 1 | 2008 | 137 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2024 | 791 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 65 | 0.060 |
Why?
| | Molecular Sequence Data | 6 | 2010 | 2914 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 627 | 0.060 |
Why?
| | Survival Rate | 2 | 2020 | 2052 | 0.060 |
Why?
| | Argentina | 1 | 2025 | 29 | 0.060 |
Why?
| | Canada | 2 | 2017 | 426 | 0.050 |
Why?
| | Precancerous Conditions | 1 | 2006 | 167 | 0.050 |
Why?
| | Thromboplastin | 1 | 2004 | 72 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 1999 | 115 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2024 | 55 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2008 | 1471 | 0.050 |
Why?
| | Hypoglycemic Agents | 1 | 2013 | 1404 | 0.050 |
Why?
| | Protein Binding | 4 | 2010 | 2277 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 3113 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 309 | 0.050 |
Why?
| | Ovariectomy | 2 | 2017 | 163 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 467 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2025 | 225 | 0.050 |
Why?
| | Amino Acid Sequence | 4 | 2010 | 2149 | 0.050 |
Why?
| | Postmenopause | 3 | 2017 | 391 | 0.050 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 31 | 0.050 |
Why?
| | Genome, Human | 1 | 2024 | 429 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2005 | 630 | 0.050 |
Why?
| | Immune Evasion | 1 | 2022 | 67 | 0.040 |
Why?
| | Larva | 2 | 1993 | 242 | 0.040 |
Why?
| | Biology | 1 | 2022 | 91 | 0.040 |
Why?
| | Promegestone | 4 | 2005 | 33 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 247 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1999 | 167 | 0.040 |
Why?
| | Mifepristone | 2 | 2000 | 64 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 561 | 0.040 |
Why?
| | Drug Resistance | 2 | 2000 | 154 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 580 | 0.040 |
Why?
| | Adult | 4 | 2016 | 40538 | 0.040 |
Why?
| | Fibroblasts | 1 | 2006 | 1042 | 0.040 |
Why?
| | Zinc | 1 | 2024 | 297 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 292 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2020 | 83 | 0.040 |
Why?
| | Antigens, Nuclear | 1 | 2000 | 16 | 0.040 |
Why?
| | Exons | 2 | 1999 | 358 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2015 | 11612 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2000 | 90 | 0.040 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1999 | 55 | 0.040 |
Why?
| | Postpartum Period | 1 | 2022 | 362 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 836 | 0.040 |
Why?
| | Young Adult | 1 | 2016 | 14082 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 2006 | 936 | 0.040 |
Why?
| | Receptor Cross-Talk | 1 | 1998 | 21 | 0.040 |
Why?
| | Immunological Synapses | 1 | 2018 | 17 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2018 | 26 | 0.040 |
Why?
| | DNA Helicases | 1 | 2000 | 145 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 1998 | 69 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2008 | 8200 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 140 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1998 | 198 | 0.030 |
Why?
| | Drug Synergism | 1 | 1998 | 364 | 0.030 |
Why?
| | Oxygenases | 1 | 1997 | 13 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 48 | 0.030 |
Why?
| | Biological Transport | 1 | 1998 | 412 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1267 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1998 | 298 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 380 | 0.030 |
Why?
| | Consanguinity | 1 | 2017 | 49 | 0.030 |
Why?
| | Male | 3 | 2021 | 72317 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2005 | 1309 | 0.030 |
Why?
| | STAT3 Transcription Factor | 1 | 1998 | 208 | 0.030 |
Why?
| | Ribosomal Proteins | 1 | 1997 | 93 | 0.030 |
Why?
| | Carcinogens | 1 | 1997 | 123 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 162 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 273 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1999 | 451 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2010 | 362 | 0.030 |
Why?
| | Siblings | 1 | 2017 | 196 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2000 | 410 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1099 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 514 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 454 | 0.030 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 3 | 2000 | 15 | 0.030 |
Why?
| | Histones | 2 | 2014 | 658 | 0.030 |
Why?
| | Proto-Oncogene Protein c-fli-1 | 1 | 2015 | 29 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1272 | 0.030 |
Why?
| | Base Sequence | 3 | 2008 | 2188 | 0.030 |
Why?
| | Keratin-5 | 1 | 2014 | 48 | 0.030 |
Why?
| | Nuclear Receptor Coactivator 1 | 2 | 2006 | 10 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 748 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 480 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 428 | 0.020 |
Why?
| | DNA Primers | 2 | 2008 | 517 | 0.020 |
Why?
| | Dipeptides | 1 | 1993 | 57 | 0.020 |
Why?
| | Chromatography | 1 | 1992 | 27 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2017 | 660 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1993 | 415 | 0.020 |
Why?
| | Elastin | 1 | 1992 | 84 | 0.020 |
Why?
| | Hydrolysis | 1 | 1992 | 201 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1992 | 103 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1842 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 559 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5367 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2010 | 204 | 0.020 |
Why?
| | Oligopeptides | 1 | 1992 | 268 | 0.020 |
Why?
| | Cell Size | 1 | 2010 | 92 | 0.020 |
Why?
| | COS Cells | 2 | 2003 | 181 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2010 | 32 | 0.020 |
Why?
| | DNA, Helminth | 1 | 2010 | 25 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2010 | 85 | 0.020 |
Why?
| | Collagen | 1 | 1992 | 468 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2010 | 151 | 0.020 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 2 | 2000 | 14 | 0.020 |
Why?
| | Matrix Metalloproteinase 11 | 1 | 2008 | 4 | 0.020 |
Why?
| | DNA Methylation | 1 | 2014 | 682 | 0.020 |
Why?
| | Phosphorylation | 2 | 2005 | 1763 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5633 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3202 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2008 | 90 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2005 | 2039 | 0.020 |
Why?
| | Cell Division | 2 | 2000 | 780 | 0.020 |
Why?
| | Myometrium | 1 | 2008 | 39 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 1992 | 564 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 79 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2008 | 166 | 0.020 |
Why?
| | Trypan Blue | 1 | 2006 | 5 | 0.020 |
Why?
| | Comet Assay | 1 | 2006 | 14 | 0.020 |
Why?
| | United States | 1 | 2025 | 15746 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 55 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2006 | 75 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 86 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2006 | 149 | 0.010 |
Why?
| | Mutant Proteins | 1 | 2006 | 105 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 2 | 2000 | 685 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4283 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2006 | 225 | 0.010 |
Why?
| | Androstenes | 1 | 2005 | 17 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 242 | 0.010 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2006 | 163 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2005 | 37 | 0.010 |
Why?
| | Levonorgestrel | 1 | 2005 | 35 | 0.010 |
Why?
| | Desogestrel | 1 | 2005 | 46 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 362 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2006 | 173 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2005 | 144 | 0.010 |
Why?
| | Sucrose | 1 | 2004 | 112 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2006 | 321 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 257 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 499 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 858 | 0.010 |
Why?
| | DNA Damage | 1 | 2006 | 436 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 324 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 649 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2003 | 392 | 0.010 |
Why?
| | Progesterone Congeners | 1 | 2002 | 14 | 0.010 |
Why?
| | Mutagenesis | 1 | 2003 | 193 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 194 | 0.010 |
Why?
| | Uterus | 1 | 2003 | 229 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11749 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1113 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 380 | 0.010 |
Why?
| | Ku Autoantigen | 1 | 2000 | 12 | 0.010 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2000 | 15 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2000 | 99 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1358 | 0.010 |
Why?
| | Culture Techniques | 1 | 1999 | 67 | 0.010 |
Why?
| | Methionine | 1 | 2000 | 163 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2003 | 707 | 0.010 |
Why?
| | Growth Substances | 1 | 1999 | 141 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1525 | 0.010 |
Why?
| | Estrogen Receptor beta | 1 | 1999 | 42 | 0.010 |
Why?
| | Cricetinae | 1 | 1999 | 301 | 0.010 |
Why?
| | Phosphotyrosine | 1 | 1998 | 40 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 1998 | 56 | 0.010 |
Why?
| | Premenopause | 1 | 1999 | 123 | 0.010 |
Why?
| | RNA | 1 | 2005 | 942 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2017 | 16954 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 154 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1998 | 25 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 1998 | 145 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1999 | 513 | 0.010 |
Why?
| | Estrogen Antagonists | 1 | 1998 | 49 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 179 | 0.010 |
Why?
| | Isomerism | 1 | 1997 | 57 | 0.010 |
Why?
| | Gene Deletion | 1 | 1999 | 388 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 272 | 0.010 |
Why?
| | Leucine Zippers | 1 | 1997 | 16 | 0.010 |
Why?
| | Yeasts | 1 | 1997 | 51 | 0.010 |
Why?
| | Autoantigens | 1 | 2000 | 432 | 0.010 |
Why?
| | Blotting, Western | 1 | 1998 | 1207 | 0.010 |
Why?
| | Child | 1 | 2015 | 22649 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1998 | 1058 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 7120 | 0.010 |
Why?
| | Cell Line | 1 | 1998 | 2911 | 0.010 |
Why?
| | Cytokines | 1 | 1999 | 2101 | 0.010 |
Why?
| | Models, Biological | 1 | 1998 | 1838 | 0.010 |
Why?
|
|
Richer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|